Ping Wang1, Joey Leung2, Alice Lam2, Seoyeon Lee1, Daniel R Calabrese3, Steven R Hays1, Jeffery A Golden1, Jasleen Kukreja2, Jonathan P Singer1, Paul J Wolters1, Qizhi Tang2, John R Greenland4. 1. Department of Medicine, University of California San Francisco, San Francisco, California. 2. Department of Surgery, University of California San Francisco, San Francisco, California. 3. Department of Medicine, University of California San Francisco, San Francisco, California; Medical Service, San Francisco VA Health Care System, San Francisco, California. 4. Department of Medicine, University of California San Francisco, San Francisco, California; Medical Service, San Francisco VA Health Care System, San Francisco, California. Electronic address: john.greenland@ucsf.edu.
Abstract
BACKGROUND: Telomere dysfunction is associated with idiopathic pulmonary fibrosis (IPF) and worse outcomes following lung transplantation. Telomere dysfunction may impair immunity by upregulating p53 and arresting proliferation, but its influence on allograft-specific immune responses is unknown. We hypothesized that subjects undergoing lung transplantation for IPF would have impaired T cell proliferation to donor antigens. METHODS: We analyzed peripheral blood mononuclear cells (PBMC) from 14 IPF lung transplant recipients and 12 age-matched non-IPF subjects, before and 2 years after transplantation, as well as PBMC from 9 non-transplant controls. We quantified T cell proliferation and cytokine secretion to donor antigens. Associations between PBMC telomere length, measured by quantitative PCR, and T cell proliferation to alloantigens were evaluated with generalized estimating equation models. RESULTS: IPF subjects demonstrated impaired CD8+ T cell proliferation to donor antigens pre-transplant (p < 0.05). IL-2, IL-7, and IL-15 cytokine stimulation restored T cell proliferation, while p53 upregulation blocked proliferation. IPF subjects had shorter PBMC telomere lengths than non-IPF subjects (p < 0.001), and short PBMC telomere length was associated with impaired CD8+ T cell proliferation to alloantigens (p = 0.002). CONCLUSIONS: IPF as an indication for lung transplant is associated with short PBMC telomere length and impaired T cell responses to donor antigens. However, the rescue of proliferation following cytokine exposure suggests that alloimmune anergy could be overcome. Telomere length may inform immunosuppression strategies for IPF recipients. Published by Elsevier Inc.
BACKGROUND: Telomere dysfunction is associated with idiopathic pulmonary fibrosis (IPF) and worse outcomes following lung transplantation. Telomere dysfunction may impair immunity by upregulating p53 and arresting proliferation, but its influence on allograft-specific immune responses is unknown. We hypothesized that subjects undergoing lung transplantation for IPF would have impaired T cell proliferation to donor antigens. METHODS: We analyzed peripheral blood mononuclear cells (PBMC) from 14 IPF lung transplant recipients and 12 age-matched non-IPF subjects, before and 2 years after transplantation, as well as PBMC from 9 non-transplant controls. We quantified T cell proliferation and cytokine secretion to donor antigens. Associations between PBMC telomere length, measured by quantitative PCR, and T cell proliferation to alloantigens were evaluated with generalized estimating equation models. RESULTS: IPF subjects demonstrated impaired CD8+ T cell proliferation to donor antigens pre-transplant (p < 0.05). IL-2, IL-7, and IL-15 cytokine stimulation restored T cell proliferation, while p53 upregulation blocked proliferation. IPF subjects had shorter PBMC telomere lengths than non-IPF subjects (p < 0.001), and short PBMC telomere length was associated with impaired CD8+ T cell proliferation to alloantigens (p = 0.002). CONCLUSIONS: IPF as an indication for lung transplant is associated with short PBMC telomere length and impaired T cell responses to donor antigens. However, the rescue of proliferation following cytokine exposure suggests that alloimmune anergy could be overcome. Telomere length may inform immunosuppression strategies for IPF recipients. Published by Elsevier Inc.
Authors: Chad A Newton; David Zhang; Justin M Oldham; Julia Kozlitina; Shwu-Fan Ma; Fernando J Martinez; Ganesh Raghu; Imre Noth; Christine Kim Garcia Journal: Am J Respir Crit Care Med Date: 2019-08-01 Impact factor: 21.405
Authors: Byron B Au-Yeung; Geoffrey Alexander Smith; James L Mueller; Cheryl S Heyn; Rebecca Garrett Jaszczak; Arthur Weiss; Julie Zikherman Journal: J Immunol Date: 2017-02-03 Impact factor: 5.422
Authors: Hilary E Faust; Jeffrey A Golden; Raja Rajalingam; Angelia S Wang; Gary Green; Steven R Hays; Jasleen Kukreja; Jonathan P Singer; Paul J Wolters; John R Greenland Journal: Thorax Date: 2017-04-26 Impact factor: 9.139
Authors: Aparna C Swaminathan; Megan L Neely; Courtney W Frankel; Fran L Kelly; Slavé Petrovski; Michael T Durheim; Erika Bush; Laurie Snyder; David B Goldstein; Jamie L Todd; Scott M Palmer Journal: Chest Date: 2019-04-09 Impact factor: 9.410
Authors: K Hiyama; Y Hirai; S Kyoizumi; M Akiyama; E Hiyama; M A Piatyszek; J W Shay; S Ishioka; M Yamakido Journal: J Immunol Date: 1995-10-15 Impact factor: 5.422
Authors: Pornima Phatak; Fangping Dai; Melody Butler; M P Nandakumar; Peter L Gutierrez; Martin J Edelman; Hans Hendriks; Angelika M Burger Journal: Clin Cancer Res Date: 2008-07-15 Impact factor: 12.531
Authors: Diletta Di Mitri; Rita I Azevedo; Sian M Henson; Valentina Libri; Natalie E Riddell; Richard Macaulay; David Kipling; Maria V D Soares; Luca Battistini; Arne N Akbar Journal: J Immunol Date: 2011-07-25 Impact factor: 5.422